Navigate Common Hurdles With GLP-1 Agonists
February 2024
Questions are rolling in about GLP-1 agonists...dulaglutide (Trulicity), liraglutide (Victoza), semaglutide (Ozempic, etc), etc.
It’s partly because these meds are a first-line option for type 2 diabetes with compelling indications...such as CV or kidney disease.
Be ready to navigate common hurdles and guide appropriate use.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive